Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Unstable angina Age: Adult |
Dose: Intravenous – 180 mcg/kg via intravenous injection followed by 2 mcg/kg per minute by intravenous infusion Duration: for up to 72 hours Note: If percutaneous coronary intervention (PCI) is performed during therapy, infusion should be continued for 18-24 hours after procedure, up to a maximum total duration of 96 hours of therapy. |
|
Indication: Angioplasty Age: Adult |
Dose: Intravenous – Initially, 180 mcg/kg via intravenous injection, followed by 2 mcg/kg/minute via intravenous infusion. A second dose of 180 mcg/kg via intravenous injection should be given 10 minutes after the first dose. Duration: Continue infusion until hospital discharge or for up to 18-24 hours Note: Minimum treatment duration: 12 hours. The initial dose is to be given immediately before the procedure. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: Tablet – No approved pediatric dosage available Note: No approved pediatric dosage available |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Acute Coronary Syndromes Condition: Renal Impairment (Creatinine Clearance less than 50 mL/minute) |
Dose: Intravenous – 180 mcg/kg Frequency: Bolus, then continuous infusion 1 mcg/kg/minute |
|
Indication: Percutaneous Coronary Intervention Condition: Renal Impairment (Creatinine Clearance less than 50 mL/minute) |
Dose: Intravenous – 180 mcg/kg Frequency: Bolus, then continuous infusion 1 mcg/kg/minute with another 180 mcg/kg intravenous bolus 10 minutes after first one |
Administration
- Must be administered by healthcare professional
- Given as IV infusion
Side Effect
- Bleeding (8%)
- Hypotension (7%)
- Thrombocytopenia (2.3%)
- Injection site reaction
- Hypersensitivity
- Intracranial hemorrhage
- Pulmonary hemorrhage
- Thrombocytopenia
- GI hemorrhage
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Heparin, Other Anticoagulants (Warfarin, Heparin, Dabigatran, Rivaroxaban, Apixaban, Edoxaban), Antiplatelet & thrombolytic agents
|
Increased risk of bleeding
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Active Bleeding
|
Risk of severe hemorrhage
|
|
Hemorrhagic Disorders
|
Increased bleeding risk
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Vials should be stored refrigerated at 2-8° C
Vials may be transferred to room temperature storage for up to 2 months.
Unused portion left in the vial should be discarded.
Vials should be protected from light until administration.
Vials may be transferred to room temperature storage for up to 2 months.
Unused portion left in the vial should be discarded.
Vials should be protected from light until administration.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.